Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"

Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36

Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36

1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).

Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.